The Netherlands
VitroScan, founded in 2016, is a pioneering Dutch biotech company, strategically located at the renowned Leiden Bio Science Park. The company aims to transform cancer treatment through its mission of “Predicting treatment outcome”.
VitroScan has developed certified predictive ex vivo 3D tumor testing services that facilitate reliable treatment response predictions. Their proprietary technology stands out by providing highly reproducible drug testing within the native tumor microenvironment. This innovation is crucial for enhancing patient stratification in clinical trials.
Their clinical program involves partnerships with top-tier oncology centers, allowing correlation of ex vivo tumor sensitivity to therapies with clinical outcomes. This approach aims to refine treatment decisions and improve cancer care quality.
Recently, VitroScan secured a €1.90M grant investment from Biotech Booster on 25 November 2024. With its blend of cutting-edge technology and strategic collaborations, VitroScan is well-positioned to address significant healthcare challenges within the life sciences and biotechnology sectors.
